cytochrome P450 family 3 subfamily A member 7Genealiases: CP37 · CYPIIIA7 · P-450(HFL33) · P-450111A7 · P450-HFLA · P450HLp2
Q-omics provides the consensus-scored CYP3A7 profile across patient tissues and cancer cell-line models. CYP3A7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP3A7 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, CYP3A7 RNA expression shows 18,923 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where CYP3A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP3A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP3A7 survival associations across molecular data types. CYP3A7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP3A7 RNA expression–survival associations across cancer types. High CYP3A7 expression shows unfavorable associations in LUSC and LGG, but favorable associations in KIRC, ACC, BRCA and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP3A7 RNA expression.
This table summarizes CYP3A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CYP3A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP3A7 shows lower tumor expression in KIRP, LUAD, LUSC, LIHC and CHOL and higher tumor expression in KICH. The KIRP box plot shows higher CYP3A7 RNA expression in normal versus tumor tissue (log2 FC = −1.334, t-test p < 0.001).
This table shows molecular features associated with CYP3A7 in patient tissues and cancer cell lines. In patient samples, CYP3A7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP3A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
